Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration

British Journal of Ophthalmology

Volumn 98, Issue 9, 2014, Pages 1186-1191

  Suzuki, Misa ^a   Nagai, Norihiro ^a   Izumi Nagai, Kanako ^a   Shinoda, Hajime ^a   Koto, Takashi ^a   Uchida, Atsuro ^a   Mochimaru, Hiroshi ^a   Yuki, Kenya ^a   Sasaki, Mariko ^a   Tsubota, Kazuo ^a   Ozawa, Yoko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; EYE FUNDUS; EYE REFRACTION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIUM; PREDICTION; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETROSPECTIVE STUDY; RISK FACTOR; SLIT LAMP; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; VISUAL ACUITY;

DEGENERATION; MACULA; NEOVASCULARISATION; RETINA; TREATMENT MEDICAL;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROGNOSIS; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE; VISUAL ACUITY;

EID: 84906937127     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-304670     Document Type: Article

References (17)

1. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9(Suppl 1):2-10. (Pubitemid 38747842)
2. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16. (Pubitemid 40051904)
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
4. Brown DM, Kaiser PK, Michels M, et al . Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
5. Lux A, Llacer H, Heussen FM, et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91:1318-22. (Pubitemid 47492865)
6. Krebs I, Glittenberg C, Ansari-Shahrezaei S, et al. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol 2013;97:1443-6.
7. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-45.
8. Yamashiro K, Tomita K, Tsujikawa A, et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 2012;154:125-36.
9. Kruger Falk M, Kemp H, Sorensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol 2013;155:89-95.e3.
10. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
11. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
12. Hikichi T, Higuchi M, Matsushita T, et al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol 2012;154:117-24.e1.
13. Friedlander M. Fibrosis and diseases of the eye. J Clin Invest 2007;117:576-86. (Pubitemid 46348512)
14. Marmor MF. Control of subretinal fluid: experimental and clinical studies. Eye (Lond) 1990;4(Pt 2):340-4. (Pubitemid 20307091)
15. Saito M, Iida T, Kano M. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 2012;153:504-14.e1.
16. Gharbiya M, Allievi F, Recupero V, et al. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results. Retina 2009;29:740-9.
17. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122-9.